Objective: This study aims to assess the overall safety and potential endometrium-stimulating effects of soy isoflavone tablets consumed (3 y) by postmenopausal women and to determine endometrial thickness response to treatment among compliant women, taking into account hormone concentrations and other hypothesized modifying factors.
S
oy isoflavone supplements, which have been promoted in the lay press, are very popular as an alternative to hormone therapy for perimenopausal and postmenopausal women. Despite the widespread use of soy isoflavones and published efficacy trials using soy isoflavones for a variety of outcomes, very few studies have reported on adverse events or safety outcomes in midlife women. Yet, it is critical to examine the long-term safety of long-term soy isoflavone exposure in humans, particularly because high doses can be ingested with supplements. Indeed, soy isoflavone tablets easily allow intake in excess of isoflavones 100 mg/dayVfive times that of isoflavone intake from typical Asian diets. 1 One long-term (3-y) study 2 indicated that soy isoflavone (extract form) intake was safe for the endometrium and breast, whereas another (2-y) study 3 demonstrated that soy hypocotyl isoflavones (80 or 120 mg) did not adversely affect endometrial thickness. Another recent (1-y) study 4 showed that soy isoflavones (60 mg) combined with Lactobacillus sporogenes were safe for the endometrium, mammary glands, and liver. Indeed, a 2-year study 5 indicated that genistein (54 mg/d), the predominant soybean isoflavone, reduced the mean number of hot flushes per day but did not affect the endometrium. Another small randomized cross-over design study 6 noted that neither a lowisoflavone diet nor a high-isoflavone diet for 3 months had a significant effect on either vaginal cytology or endometrial biopsy results. In contrast to these studies, one report 7 revealed that long-term (up to 5 y) soy isoflavone treatment (150 mg/d) was associated with increased (3.8%) occurrence of endometrial hyperplasia (five with simple hyperplasia and one with complex hyperplasia) at 60 months but not at 30 months, with no cases of endometrial carcinoma in either group. Although most studies have demonstrated safety, additional long-term studies are needed to corroborate the stimulatory or nonstimulatory effects of these compounds on the endometrium and to report on adverse events and overall safety-related outcomes. Unique features of the current study were its long duration, realistic daily isoflavone doses, robust sample size, excellent rates of compliance during the 3-year intervention, adverse event monitoring throughout the study, and longitudinal modeling of multiple factors hypothesized to modify endometrial thickness response to treatment. The overall objective of this double-blind randomized controlled trial was to determine whether long-term (3-y) intake of soy isoflavone tablets by postmenopausal women was related, in general, to adverse events and, in particular, to hormone concentrations, endometrial thickness, or both.
METHODS

Study design
Participants in the current study were from the parent trial Soy Isoflavones for Reducing Bone Loss (SIRBL) Study, 8 whose primary objective was to determine the 3-year effects of two doses (80 or 120 mg/d) of isoflavones (extracted from soybeans) on lumbar spine and total proximal femur bone mineral density (BMD) in at-risk postmenopausal women. The overall objective of the current study was to determine whether there was a treatment effect on circulating hormones, adverse events, and/or endometrial thickness. A secondary objective was to determine endometrial thickness response to treatment among compliant women, taking into account hormone concentrations and other hypothesized factors that may modify response to treatment or that may be related to endometrial thickness. These modulating factors included hormones (17A-estradiol, free estradiol, or bioavailable estradiol; estrone sulfate; sex hormoneYbinding globulin [SHBG] ; and thyroid-stimulating hormone [TSH]); age or estrogen exposure or time since last menstrual period (TLMP); body mass index (BMI) or wholebody fat mass; alcohol intake; and duration of lactation in relation to pregnancies carried to term. Healthy postmenopausal women aged 45. 8 Our study protocol, data and safety monitoring plan, consent form, and participant-related materials were approved by the respective Institutional Review Boards at ISU (ID 02-199) and UCD (ID 200210884-2) . Approval for dual-energy x-ray absorptiometry (DXA) procedures was obtained from each institution's Institutional Review Board and from the State Department of Public Health in Iowa and California. At prebaseline screening, each woman was provided a written description, verbal explanation, and an informed consent form (which was signed after staff responded to her questions) before any study procedure.
Participant screening and selection
We recruited participants (2003 through 2005) from the state of Iowa and the greater Sacramento and Bay Area regions in northern California primarily through direct mailing lists, stories in local newspapers, and local/regional radio advertisements. Women who responded (N = 5,255) to outreach materials were screened initially via telephone ( Fig. 1 ) to identify healthy women younger than 65 years who had undergone natural menopause (cessation of menses from 1 through 8 y), were not experiencing excessive vasomotor symptoms, were nonsmokers, and had a BMI from 18.5 through 29.9 kg/m 2 . We excluded vegans because they would probably be soy food consumers, as well as women who had high alcohol intake (97 servings/wk) because alcohol interferes with hormone metabolism. 9 We excluded women who had been diagnosed as having a chronic disease, who had a first-degree relative with breast cancer, or who were on long-term medications (current: cholesterol-lowering or antihypertensive drugs; past 3 mo: antibiotics; past 6 mo: calcitonin, estrogen/progestogen creams; past 12 mo: oral hormones/estrogen or selective estrogen receptor modulators; ever: bisphosphonates).
Women who met the initial screening criteria (N = 677) were invited to the clinic for further eligibility assessment (Fig. 1) . We measured height and weight to confirm BMI and used a Delphi-W QDR DXA bone densitometer (Hologic Inc, Bedford, MA) to assess BMD eligibility. Because the SIRBL Study focused on disease prevention in women who had Bnormal[ BMD, we excluded women with low (91.5 SD below the mean for young adults) or high (91.0 SD above the mean) lumbar spine and/or proximal femur BMD T scores and those with evidence of previous or existing spinal fractures. Once a woman qualified on BMD, she had blood drawn for chemistry profiling. We excluded women with laboratory evidence of diabetes mellitus; abnormal renal, liver, and/or thyroid function; or abnormal lipid profile. Based on our entry criteria, we randomly assigned 255 participants to treatment.
Each participant obtained a signed medical release form from her personal physician. She was required to complete an annual physical examination and a mammogram, as well as breast and gynecologic examinations before initiation of study treatment. We monitored endometrial thickness (measured at the thickest portion) using transvaginal ultrasound (Siemens Aspen Advanced at ISU and Siemens Accusone Sequoia at UCD) at baseline, 12 months, and 36 months. Transvaginal ultrasound evaluation included length, width, and axial measurements of the uterus and ovaries (right and left), as well as internal echo content. Gynecologists also evaluated the cul de sac (for any fluid) and the cervix. Irregularities or abnormalities in any of these structures were evaluated and documented, and follow-up medical care was provided as needed. We excluded women with endometrial thickness greater than 5.0 mm at baseline, except for those with 5.0 to 6.0 mm endometrial thickness who underwent endometrial biopsy that yielded normal results. At baseline, 11 women at UCD who had endometrial thickness greater than 5.0 mm were inadvertently started on treatment but were instructed to cease treatment because of safety concerns with isoflavone exposure. These women were invited to continue with follow-up safety examinations throughout the study. Nine women at UCD had BMI beyond our inclusion criterion (1 woman, G18.5 kg/m 2 ; 8 women, Q30.0 kg/m 2 ), 4 women at UCD did not meet the criterion for TLMP ([current age j menopause age]; 1 woman, G1 y; 3 women, 98 y), and 2 women (1 woman at UCD and 1 woman at ISU) had a lumbar spine BMD T score slightly below (j1.6) or above (+1.1) our cutoff (j1.5 to e1.0). Our Data and Safety Monitoring Board (DSMB), appointed by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, granted waivers that sanctioned continued treatment of women with values beyond our BMI, TLMP, and BMD criteria as these violations did not pose a safety threat.
Randomization and treatment
To balance treatment allocation with respect to factors that may have influenced response to treatment, we stratified the Eleven women at UCD had thickened endometria, as determined by transvaginal ultrasound (TVU), and thus did not meet the inclusion criterion (e5 mm).
c Eight women discontinued treatment but completed the trial (1 woman at ISU and 7 women at UCD). BMD, bone mineral density.
participants at each site (ISU and UCD) according to initial total proximal femur BMD (high, moderate, or low) based on Third National Health and Nutrition Examination Survey database population values. 10 Once participants met the inclusion/ exclusion criteria, they were randomly assigned at each site within each BMD stratum to one of three treatment groups: (1) placebo control, (2) 80 mg of isoflavones, or (3) 120 mg of isoflavones. The ratio of genistein to daidzein to glycitein (aglycone form) in these tablets was 1.3:1.0:0.3, similar to that found in soybeans. An independent researcher at ISU confirmed that the mean (SD) actual and formulated isoflavone doses, respectively, were similar to those tested by the Archer Daniels Midland Co (Decatur, IL), as follows: control, 0 versus 0.3 (0.4) mg; 80 mg, 89.5 (5.0) versus 84.3 (4.5) mg; 120 mg, 124.0 (7.7) versus 122.5 (3.4) mg. Participants in each group were instructed to take three compressed tablets per day. Bottles did not indicate treatment assignment to preserve the doubleblindness of the study. For further details, the reader is referred to the parent project article. 8 
Interviewer-administered validated health-related questionnaires
To verify the health status of participants and to obtain their health-related data, we used a health and medical history questionnaire at prebaseline. 11, 12 We also gathered data on prescription and over-the-counter medications (indication, dose, unit, frequency, duration, and administration route) at each time point, previous and/or present use of dietary supplements (which they were asked to discontinue), and current usual alcohol intake. Each woman was asked questions about menstrual history (eg, age at menarche and date of final period), previous use of estrogen or hormone therapy, and pregnancy and lactation history, using a reproductive history questionnaire. 13, 14 To account for habitual soy food intake and to verify avoidance of soy foods during the trial, we used a soy food questionnaire. 15 
Anthropometric measures
A trained research assistant assessed anthropometric measures for each participant. With women wearing minimal clothing, body weight (to the nearest 0.1 kg) was measured using a balance beam scale (abco Health-o-meter; Health-o-meter Inc, Bridgeview, IL) at ISU and an electronic scale (Circuits and Systems Inc, E. Rockaway, NY) at UCD. With women wearing no shoes, standing height was measured (to the nearest 0.1 cm) using a wall-mounted stadiometer (Ayrton stadiometer model S100; Ayrton Corp, Prior Lake, MN). We calculated BMI based on weight and standing height measurements.
Biologic samples
Phlebotomists collected blood samples between 7:00 and 8:00 AM after overnight fasting. We separated serum from whole blood, centrifuged it for 15 minutes (4-C) at 1,300g, and stored serum and plasma aliquots at j80-C until analysis. Certified clinical laboratories (LabCorp, Kansas City, KS, for ISU; UCD Medical Center, Sacramento, CA, for UCD) analyzed serum samples for general health markers, including complete blood count with differential, chemistry panel, and thyroid screen (TSH and free thyroxine if TSH level was abnormal). We measured (in duplicate) plasma concentrations (in batch) of ultrasensitive 17A-estradiol and estrone sulfate by radioimmunoassay (Diagnostic Systems Laboratories, Austin, TX) and SHBG by enzyme-linked immunosorbent assay (IBL America, Minneapolis, MN) at the University of Minnesota. Free estradiol (fraction not protein-bound) and bioavailable estradiol (albumin-bound plus free estradiol fractions) were calculated for each participant using the equations of Vermeulen et al 16 and the association constants estimated by Mazer. 17 All samples from a given participant were analyzed in the same batch. The intra-assay coefficients of variation were 4.4% for 17A-estradiol, 4.3% for estrone sulfate, and 5.8% for SHBG.
Monitoring adverse events
Our DSMB monitored all outcomes and adverse events semiannually, whereas we documented serious adverse events and provided details to our DSMB and respective Institutional Review Board committees within 24 hours of participant notification. We monitored adverse events using a health status update form, review of health diary and medication update, chemistry profile, and complete blood count at each visit; annual bone loss (in consultation with our DSMB; considered an adverse event if cumulative bone loss was Q8% at 12 mo, Q10% at 24 mo, or Q12% at 36 mo); and endometrial thickness via transvaginal ultrasound at 12 and 36 months. Any abnormality noted on the physical examination report constituted an adverse event. Adverse event was also defined as any self-reported health event that required treatment or that resulted in a new diagnosis or in new/worsened signs or symptoms such as blood clots, vaginal bleeding, dizziness, headaches, insomnia, or fatigue. We required follow-up with our consulting physician if change was noted in the transvaginal ultrasound scan, such as a 300% increase from baseline or thickened endometrium (95 mm) or appearance/development or increased size of a polyp, fibroid, or cyst. Our consulting physician at each site determined whether an abnormality in the scan constituted an adverse event and performed appropriate follow-up (ie, monitoring, endometrial biopsy, and hysteroscopy).
Compliance
We evaluated treatment compliance by calculating the difference between the number of tablets provided and the number of tablets returned by each woman at each visit. To classify participants as either compliant (Q80%) or noncompliant (G80%), we used the 36-month cumulative percentage of compliance. 8 Urinary isoflavone concentrations verified compliance but did not classify participants as Bcompliant[ or Bnoncompliant[ based on isoflavone excretion owing to the relatively large interindividual variability in isoflavone excretion.
Statistical power and analyses
Power analysis was based on the primary bone outcomes of interest for the overall SIRBL Study, 8 including intent-to-treat women (N = 224; control, n = 74; 80 mg/d, n = 77; 120 mg/d, n = 73), with blocking by site (ISU or UCD) and prebaseline proximal femur BMD stratum (high, moderate, or low). Statistical analyses were performed using SAS software (version 9.2; SAS Institute Inc, Cary, NC) and R software (version 3.01; The R Foundation for Statistical Computing, Vienna, Austria), with results considered statistically significant (two-sided) at P G 0.05. Descriptive statistics with 255 women at baseline included median (minimum-maximum) values for all data because the outcome data and most variables were not normally distributed. Hormone data are presented at each time point for all women who returned for visits. Change in endometrial thickness (mm) data is presented at each time point (baseline, 12 mo, and 36 mo) separately according to site because of site differences in ultrasound equipment. The primary analysis was intent-to-treat analysis, 18 which included all data from all women who had a follow-up BMD at 36 months (N = 224) regardless of treatment compliance. Because the assumption of normality was not supported by the data, we used nonparametric analysis of variance (ANOVA) to determine the effects of treatment on circulating hormone concentrations and endometrial thickness. To determine whether treatment differences were consistent across all time points, we used parallel-profile tests (based on Wilks' L criterion) for changes in endometrial thickness at each site. To determine the effects of treatment on adverse events, we used a Poisson regression model with an extra dispersion parameter that links the natural logarithms of the rates of occurrence of adverse events to treatment and site effects. The extra dispersion parameter is needed to account for overdispersion in the response variable (ie, its variance is larger than its mean). The most common adverse events according to treatment are reported.
Secondary analyses included all women from the intent-totreat analysis who were protocol-compliant (980% based on cumulative percentage of compliance) and for whom we had complete data for variables included in the models. One UCD participant did not have a baseline blood sample and thus did not remain in the analyses for compliant women. The linear mixed-effects longitudinal model assessed the effects of treatment after adjustment for covariates that might influence the response of endometrial thickness across time points. We modeled the natural logarithm of endometrial thickness to stabilize its variance. The fitted model included site and treatment as obligatory design variables. The ISU site effect was part of each model intercept, whereas the UCD site effect was indicated separately. Classes of variables modeling the outcomes of interest included biologically plausible independent variables that we hypothesized would be related to endometrial thickness, including the following: age or estrogen exposure (age at menopause j age at menarche) or TLMP at baseline; weight or whole-body fat mass at baseline; plasma concentrations of 17A-estradiol, estrone sulfate, and SHBG across time points; serum TSH concentration across time points; alcohol intake (usual weekly intake estimated from the questionnaire) at baseline; and lactation duration (in months per pregnancy carried to term). Model selection was guided by a stepwise procedure based on Akaike's information criterion to provide the best predictive model for the outcome. 19 We used a cutoff of P e 0.10 as the acceptable Type I error rate for covariates in the model to allow consideration of variables that may be borderline, in the event that they provide a greater understanding of potential biologic phenomena. After the transformation of endometrial thickness, residual diagnostics indicated homogeneous variability. No other violations of mixed-effects model assumptions emerged during the analysis.
RESULTS
Enrollment and retention of participants
Among the 677 women who completed prebaseline screening and met initial eligibility, 37.7% met subsequent criteria and were randomly assigned to treatment at each site (122 women at ISU and 133 women at UCD) within each proximal femur BMD stratum (high, moderate, or low). Among the 255 women who were randomly assigned to treatment, 31 women (12.2%) were lost to follow-up (2 women at ISU and 29 women at UCD) and 8 women (3.1%) discontinued treatment but completed the trial (1 woman at ISU and 7 women at UCD). Reasons for discontinuance and loss to follow-up are presented in Figure 1 . The 11 participants at UCD (8.3%) who had thickened endometria (95 mm; thus, they did not meet the inclusion criterion) were removed from treatment; five of these 11 women completed the study visits. Altogether, 224 women (intent-to-treat analysis) were retained (120 women at ISU and 104 women at UCD), and 216 women remained on treatment (119 women at ISU and 97 women at UCD) for 36 months. Participants in the treatment groups for the intent-to-treat and compliant models, respectively, were as follows: 74 and 72 women in the placebo control group; 77 and 67 women in the 80 mg/day group; and 73 and 69 in the 120 mg/day group.
Compliance
Based on returned tablet counts, compliance was excellent in women who remained on treatment (N = 216), with 209 (96.8%; 117 women at ISU and 92 women at UCD) of 216 women achieving compliance of 80% or more (cumulative at 36 mo). 8 One participant at UCD did not have a baseline blood sample and thus did not remain in the compliant analysis (N = 208). Median compliance (all women who remained on treatment) was likewise high but was significantly (P e 0.0001) higher at ISU (98.0%; 94.0%-99.6%) than at UCD (95.2%; 88.0%-98.2%). We noted no difference in median compliance values across the three treatment groups (P = 0.49) or across BMD strata within site (P = 0.39). Median (lower quartileupper quartile) compliance was 97.0% (93.1%-99.2%) for the placebo control group (n = 74), 96.1% (91.3%-98.6%) for the 80 mg/day group (n = 72), and 97.2% (91.8%-99.3%) for the 120 mg/day group (n = 70). Consistent with excellent compliance, median values for urinary daidzein did not change from baseline to 36 months (302-195 nmol/d; not significant) in the control group, increased from 208 to 8,706 nmol/ day in the 80 mg/day group (P e 0.0001), and increased from 304 to 11,411 nmol/day in the 120 mg/day group (P e 0.0001). Similar patterns in the excretion of other urinary isoflavone metabolites were noted among the three treatment groups. At baseline, there were no statistical differences in these characteristics among treatment groups. Four women (80 mg/d, two women; 120 mg/d, one woman; control, one woman) at University of California at Davis were beyond the range of inclusion criterion for time since last menstrual period (1 through 8 yr), but these women were included in the trial because the intervention did not pose a safety threat.
c One woman in the 120 mg/day group started hormone therapy but stopped within days; thus, the minimal value was 0.
d Statistics did not include 11 women with thickened endometria who were incorrectly randomized to treatment at University of California at Davis before receipt of their transvaginal ultrasound report results; Soy Isoflavones for Reducing Bone Loss Study discontinued treatment for these 11 women. Five of these women at University of California at Davis had endometrial thickness greater than 5.0 mm (5.5, 5.9, 6.0, 6.0, and 6.5 mm) at baseline. Four women with endometrial thickness greater than 5.5 mm underwent endometrial biopsy but had normal results; thus, these women were included in these statistics and remained on treatment.
Characteristics of participants
Descriptive characteristics and data are presented in Table 1 . We found no statistically significant differences in any of these variables at baseline among the treatment groups. Women ranged in age from 45.8 to 65.0 years. TLMP ranged from 0.8 to 10.0 years. Despite our efforts to enroll women from all racial/ ethnic backgrounds (self-reported as defined by the National Institutes of Health), we enrolled predominantly white (92%) women. At baseline, BMI ranged from 17.8 to 32.7 kg/m 2 ; approximately half of the women had BMI less than 25 kg/m 2 . Median weight and height remained stable across time, as did BMI, whole-body lean mass, and whole-body fat mass. Wholebody fat mass, as assessed by DXA, indicated wide variability among women. Further details on these results are provided in the parent project article. 8 
Serum analytes/hormones and endometrial thickness
Nonparametric ANOVA indicated no differences in circulating hormone concentrations (Table 2 ) at various time points among treatment groups. Results did not differ when analyses were performed on calculated free estradiol and bioavailable estradiol. However, there were a few site differences not attributable to treatment. At baseline, women at UCD had significantly higher estrone sulfate (P e 0.0001) and lower TSH (P = 0.0002) than women at ISU. Differences persisted for estrone sulfate at each subsequent time point (P e 0.0001) and for TSH at 6 months (P = 0.044), 12 months (P = 0.022), and 36 months (P = 0.0058). At 12 months, UCD had lower estrone sulfate (P = 0.032) in the 120 mg/day group than in the other two groups. SHBG trended higher at ISU than at UCD at baseline (P = 0.071) and 6 months (P = 0.049); otherwise, differences between sites were not noted.
Median values for endometrial thickness declined from baseline through 36 months (Fig. 2) at ISU (from 1.5 to 1.1 mm) and UCD (from 2.6 to 1.9 mm). The two geographic sites remained separate for analysis (except for the linear mixedeffects longitudinal model in Table 5 , where we accounted for site difference) because endometrial thickness (mm) values were statistically different (P e 0.0001) between sites at each time point owing to site differences in transvaginal ultrasound equipment. Although the values for endometrial thickness were approximately 30% to 40% higher at UCD than at ISU, these differences persisted throughout treatment and did not influence the interpretation of results. Based on nonparametric ANOVA for treatment differences (absolute) among groups, no differences in endometrial thickness emerged at any time point Nonparametric analysis of variance indicated that there were no treatment differences in circulating hormone concentrations at any time point, except at 12 months; University of California at Davis had lower (P = 0.032) estrone sulfate in the 120 mg/day group than in the other two groups.
b At baseline, women at University of California at Davis had significantly higher estrone sulfate (P e 0.0001) and lower thyroid-stimulating hormone (P = 0.0002) than women at Iowa State University. Differences in estrone sulfate (P e 0.0001) persisted at each subsequent time point; differences in thyroid-stimulating hormone persisted at 6 months (P = 0.044), 12 months (P = 0.022), and 36 months (P = 0.0058). Sex hormoneYbinding globulin trended higher at Iowa State University than at University of California at Davis at baseline (P = 0.071) and 6 months (P = 0.049).
(W 2 P ranged from 0.12 to 0.69). Likewise, nonparametric ANOVA indicated that treatment had no effect on percentage of change at 12 months (W 2 P = 0.46) or 36 months (W 2 P = 0.28). Parallel-profile tests (based on Wilks' L criterion) performed to determine whether treatment differences in endometrial thickness were consistent across all time points indicated that there was no interaction between treatment and time for either ISU (P = 0.41) or UCD (P = 0.70), further indicating no effect of treatment across time.
Adverse events
Adverse events (Table 3) were classified into 14 broad physiological systems: cardiovascular, endocrine, gastrointestinal, genitourinary, gynecologic, hematologic, metabolic, nervous, nonspecific (ie, bone, joint, and spine disorders, etc), ophthalmic, pathologic, pulmonary, renal, and skin. In a given system, there was a tendency for higher rates of adverse event reporting at ISU than at UCD; however, site differences were not significant, except for upper respiratory tract infection (P e 0.0001) and pathologic conditions (P = 0.0017), including sinusitis and other infections, which were more common at ISU than at UCD. The pathologic conditions that were more common at ISU than at UCD included sinusitis (23 vs 3 cases, respectively) and a variety of infections (21 vs 5 cases, respectively) such as bacterial infections, otitis media, and benign cysts.
The pathologic conditions that were more common at UCD than at ISU included malignancies (7 vs 2 cases, respectively) such as squamous cell carcinoma and carcinoid (lung) tumor. The most common adverse event, regardless of treatment group, was upper respiratory tract infection, followed by nonspecific complaints. However, we observed a significant treatment effect on the genitourinary system (P = 0.005; Table 3) , with a greater number of events in the 80 mg/day group but fewer events in the 120 mg/day group. Nevertheless, there were relatively few genitourinary events among postmenopausal women during the 3-year course. Spotting or bleeding caused by small polyps or fibroids was not related to changes in endometrial thickness. During the course of treatment, 10 women required further evaluation: 5 women (2 women at ISU and 3 women at UCD) underwent endometrial biopsy and 5 women (3 women at ISU and 2 women at UCD) underwent hysteroscopy (distributed across treatment groups), with normal pathology reported by the attending physician. No other significant treatment effect emerged for other systems. The most common adverse events with each treatment are shown in Table 4 . The number of adverse events was 412 in the control group (n = 76), 401 in the 120 mg/day group (n = 76), and 427 in the 80 mg/day group (n = 82). Given the long-term nature of this study, adverse events (other than respiratory tract infection) were relatively uncommon. One woman (120 mg/d group) had excessive lumbar spine bone loss at 24 months (28.3%) and 36 months (212.1%), and another woman (control group) had excessive proximal femur bone loss at 24 months (28.7%). Each woman with excessive bone loss was notified and advised to report these results to her primary care physician for follow-up care. We documented 18 serious adverse events among 16 women across 36 months: 4 serious adverse events in the control group, 8 serious adverse events in the 80 mg/day group, and 6 serious adverse events in the 120 mg/day group. In the control group, one woman had a myocardial infarction, one woman had breast reduction, and one woman had two occurrences of benign parathyroid tumors. In the 80 mg/day group, one woman had two occurrences of anterior cystocele (bladder disorder), one woman had a traumatic bone fracture, one woman had hip replacement, one woman died of infection, one woman contracted malaria while traveling overseas, one woman had a carcinoid tumor, and one woman had breast cancer. In the 120 mg/day group, one woman had a benign parathyroid tumor, one woman had hysterectomy, two women had traumatic bone fractures, and two women had breast cancer. Each serious adverse event was carefully reviewed by our DSMB and deemed not related to treatment.
Predictors of endometrial thickness
The model predicting endometrial thickness response (using the natural logarithm) to treatment among compliant women (N = 208) across time points (Table 5 ) was significant (P e 0.0001), indicating that estrogen exposure (P = 0.0013), plasma 17A-estradiol (P = 0.0086), and alcohol intake (P = 0.023) contributed significantly to endometrial thickness response. Although neither the 80 mg/day treatment dose nor the 120 mg/day treatment dose exerted an effect (P = 0.57 and P = 0.43, respectively) on endometrial thickness across time, site (consistently higher values at UCD) and time (endometrial thickness decreased at both sites from baseline through 36 mo) both exerted significant (P e 0.0001) effects. However, the interaction Incidence rates were calculated using expected counts divided by exposure time. For women who completed the entire study, the exposure time was 36 months; for women who dropped out, exposure time was the time point at which the woman was last examined plus one half of the next time interval. between treatment and time (log likelihood ratio = 3.996; df = 2) was not significant (P = 0.14). In this group of women, there was greater loss in endometrial thickness as estrogen exposure or plasma 17A-estradiol decreased. The decline in endometrial thickness lessened as alcohol intake increased. Serum TSH remained in the model but did not reach statistical significance (P = 0.066). The independent variables that did not remain in the model were body weight or body fat mass, lactation duration, plasma estrone concentration, and SHBG.
DISCUSSION
The current study is unique in that we assessed the long-term overall safety and potential endometrium-stimulating effects of soy isoflavone tablets, using transvaginal ultrasound, among a fairly large group of postmenopausal women who consumed (with excellent compliance) soy isoflavone (80 or 120 mg/d) tablets for 3 years. Nonetheless, there were limitations to this study. We had numerous exclusion criteria; these women were relatively healthy and agreed to participate for three full years. The women were sampled from two distinct US locations and hence did not represent women from the east coast or southern states. Despite our attempts to include a broader spectrum of women, they were relatively homogeneous from a socioeconomic, racial/ethnic, and cultural perspective. Thus, these women were not necessarily representative of postmenopausal women in general. In addition, a greater number of women at UCD (n = 29) than at ISU (n = 2) were lost to follow-up in part because more women at UCD than at ISU relocated during the study. We also speculated that because the ISU site was more rural than the UCD site, women in Iowa were more accustomed to traveling long distances for services and, thus, most ISU women did not find it burdensome to attend visits (many traveled for 3-4 h; a few had moved to distant states but remained in the study). We also speculated that the more urban lifestyle at the UCD site imposed different and perhaps greater challenges to traveling to the clinic site. Although both sites implemented similar follow-up contact procedures, the UCD site experienced greater staff turnover during the course of the study and hence had less continuity of personnel contact than participants at ISU.
We report no treatment effect on circulating hormone concentrations (or on other circulating analytes not reported), no treatment effect on endometrial thickness, and no appreciable treatment effect on adverse events, except that the 80 mg/day group had more (27 events) genitourinary adverse events than the 120 mg/day group (8 events). Most of these genitourinary adverse events were urinary tract infections, clustering in a small group of women. Collectively, these results indicate that soy isoflavones did not adversely impact circulating hormone concentrations or the genitourinary system in these postmenopausal women. The lower number of genitourinary adverse events at the higher dose suggested the relative safety of soy isoflavones for this system. By a wide margin, the greatest number of adverse events was observed for upper respiratory tract infection (Table 4) , particularly among women in Iowa (Table 3 , pulmonary system), presumably attributable to a longer flu season than in California.
Comparisons herein are limited to the human model because there are sufficient data to provide insights solely from the human literature. The current study did not document treatment-induced effects on serum 17A-estradiol, free estradiol, bioavailable estradiol, estrone sulfate, SHBG, or TSH, consistent with a systematic review and meta-analysis that reported no statistically significant effect of soy or isoflavones on 17A-estradiol, estrone, or SHBG in postmenopausal women. 20 Our results are also similar to those of a study of red cloverYderived isoflavones, 21 Natural logarithm of endometrial thickness as variance stabilizing transformation.
c P values were based on asymptotic normality of t distribution; variables left in the model were significant at P e 0.10 (acceptable Type I error rate in modelingthat these doses of soy isoflavones do not negatively impact thyroid function in postmenopausal women. In addition, we report no effect of treatment on endometrial thickness at any time point, with a decline in thickness at both sites across treatments, particularly from baseline to 12 months. Before the initiation of our clinical trial, limited data on the endometrial safety of isoflavones in humans had been published, with few exceptions. A small randomized cross-over design study 6 indicated that neither a low-isoflavone diet (1.0 mg/kg/d) nor a high-isoflavone diet (2.0 mg/kg/d) for 3 months had a significant effect on either vaginal cytology or endometrial biopsy results in premenopausal women. In addition, Upmalis et al 24 reported no change in endometrial thickness or vaginal maturation index with either treatment (genistein 50 mg/d + daidzein vs placebo) after 12 weeks. However, after our project was well under way 25<27 but before the publication of the results from this article, 2, 3, 5 additional studies have been published, more firmly establishing the endometrial safety of isoflavones. Earlier studies were relatively short term (e12 mo), whereas later studies demonstrating safety were based on longer-term exposure to soy isoflavone treatment.
Han et al 25 reported that soy isoflavones (100 mg/d) for 4 months had no proliferative effect on the endometrium, as assessed by transvaginal ultrasound examination. Likewise, Penotti et al 26 documented that soy isoflavones (72 mg/d) for 6 months had no stimulatory effect on the endometrium, as assessed by transvaginal ultrasound examination, or on uterine pulsatility index, as assessed by Doppler velocimetry. to test the hypothesis that 6 months of soy protein with isoflavones would oppose the proliferative effects of exogenous estradiol on the endometrium. Although soy protein with isoflavones was not found to protect the endometrium from exogenous estradiol, they reported that endometrial hyperplasia, endometrial stromal and epithelial cellular proliferation, and endometrial thickness were similarly affected in all groups. The design of this last short-term study was not similar to ours despite providing similar daily isoflavone doses but provided valuable information that soy protein isolate with isoflavones did not protect the endometrium from estradiol-induced hyperplasia in postmenopausal women.
Among longer-term studies, D'Anna et al 5 indicated that genistein (54 mg/d) improved vasomotor symptoms at 12 months, and they found no adverse effect on the endometrium or vagina either at baseline or after 24 months. A 24-month (2-y) study 3 using soy hypocotyl isoflavones (80 or 120 mg/d; doses similar to ours) reported transvaginal ultrasound measurements from a California cohort (N = 116) with no significant differences in endometrial thickness among the three treatment groups. Likewise, Palacios et al 2 did not report any significant change in endometrial thickness (98.4% inactive or atrophic and 0.3% proliferative at 12 mo), with only one case of simple hyperplasia diagnosed among 197 postbaseline interpretable biopsies. Global safety was rated as either excellent or good by 99% of investigators and women after 36 months of isoflavone (70 mg/d) extract treatment. In contrast, one report 7 indicated that longer-term (up to 5 y) soy isoflavone exposure was associated with increased (3.8%) occurrence of endometrial hyperplasia (five women with simple hyperplasia and one woman with complex hyperplasia), whereas no cases of endometrial carcinoma occurred in either group. This last study used a relatively high dose of isoflavones (150 mg/d) and did not demonstrate hyperplasia at 30 months but reported hyperplasia with longer exposure (60 mo).
Collectively, these studies demonstrate that there is evidence for the endometrial safety of isoflavones across a 3-year period in that these compounds do not exert uterotrophic effects when consumed at doses of 120 mg/day or less. Only one study 7 has raised concerns with use longer than 36 months (5 y), indicating that a higher dose of isoflavones (150 mg/d) may cause a slightly higher risk of simple endometrial hyperplasia in some (G3%) women. In contrast, our study did not find evidence of endometrial stimulation with soy isoflavone 120 or 80 mg/day for 3 years in these postmenopausal women. In addition, there are no data to suggest that soy food intake promotes endometrial hyperplasia.
Although soy isoflavone treatment did not alter the decline in endometrial thickness, a few factors slightly modified the decline in endometrial thickness from baseline to 36 months. For example, women in this study who had longer lifetime estrogen exposure and higher circulating 17A-estradiol concentration experienced less loss in endometrial thickness from baseline to 36 months. Interestingly, estrogen exposure was not related to plasma 17A-estradiol (r = j0.05); thus, each of these estrogen variables uniquely prevented the loss of endometrial thickness. We were somewhat surprised that women with higher usual alcohol intake experienced less decline (slight) in endometrial thickness from baseline to 36 months, considering that our participants were not heavy drinkers. Evidence indicates that alcohol intake elevates circulating estrogen, 28 ,29 which in turn might alter endometrial thickness; however, further large studies have not corroborated an association between alcohol intake and endometrial cancer risk, 30, 31 thereby dispelling the notion that alcohol intake promotes endometrial cancer risk. Nevertheless, the predominant factor that contributed, as expected, to the decline in endometrial thickness was time, reflecting the increase in TLMP.
CONCLUSIONS
Regardless of treatment, postmenopausal women in this study experienced a progressive decrease in endometrial thickness (which was particularly marked from baseline to 12 mo) across time. Our study verifies the long-term overall safety of soy isoflavone tablets (80 or 120 mg/d) intake by postmenopausal women who display excellent compliance. We find no evidence of treatment effects on endometrial thickness, adverse events, or circulating hormone concentrations, most notably thyroid function, across a 3-year period.
